

Special Issue

Stem Cells in Leukemia: From Biological Properties to Therapeutic Targeting

Message from the Guest Editor

Understanding heterogeneity in cancer is becoming crucial for the development of effective therapeutic strategies. The proposed hierarchical structure of some tumors is one aspect of cancer heterogeneity, with “cancer stem-cells” (CSCs) being able to propagate the tumor and playing a role in tumor persistence and the development of therapy-resistance. Hematological malignancies have necessitated pioneering studies of CSCs, with leukemia stem cells (LSCs) being associated with unique intrinsic and extrinsic biological properties, making them selectively unresponsive to conventional therapies. This Special Issue will focus on the characterization of biological mechanisms responsible for therapy escape in LSCs and will touch upon novel therapeutic strategies accounting for the role of CSCs.

Guest Editor

Dr. Alice Giustacchini

Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, Zayed Centre for Research into Rare Disease in Children, London WC1N 1DZ, UK

Deadline for manuscript submissions

closed (29 May 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/52729

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)